Metformin is an oral tablet for adults with type 2 diabetes. It helps lower blood glucose by reducing liver glucose production and improving insulin sensitivity.
Metformin is an oral tablet containing metformin hydrochloride for adults with type 2 diabetes. It belongs to the biguanide class of glucose-lowering medicines.
Metformin contains metformin hydrochloride in tablet form. The dose is stated on the pack — follow the leaflet. It belongs to the biguanide class of glucose-lowering medicines.
The dose is stated on the pack — follow the leaflet. The tablet should be taken according to the prescribed regimen. The final daily dose must reflect the prescription, kidney function, age, other medicines, and the tablet formulation.
Common administration principles include:
Metformin treatment is often increased slowly. A gradual increase gives the intestine time to adapt and may reduce diarrhoea and cramping. Gastrointestinal symptoms can still occur even when the dose is increased carefully.
A missed dose should not be replaced with an extra dose at once. Increasing the dose increases the chance of nausea, diarrhoea, abdominal pain, and other adverse effects without reliably improving glucose control.
Kidney function should be assessed before treatment and during continued use. NICE guidance uses estimated glomerular filtration rate, or eGFR, to guide metformin dosing and suitability [3]. An eGFR is a blood-test estimate of how well the kidneys filter waste.
Metformin reduces glucose production by the liver and improves insulin sensitivity in muscle and other tissues. These effects reduce the amount of glucose entering the bloodstream and help cells use glucose more efficiently. Metformin does not stimulate the pancreas to release extra insulin.
Metformin is used mainly for type 2 diabetes, alongside eating-pattern changes and physical activity. It may be prescribed alone or combined with other diabetes medicines when one treatment does not provide sufficient glucose control. The medicine does not stimulate the pancreas to release extra insulin, so it has a lower risk of hypoglycaemia when used alone than medicines that directly increase insulin secretion [1].
The European Medicines Agency recognises metformin as a treatment for type 2 diabetes when diet and physical activity alone do not provide adequate control. Guidance from the World Health Organization also places metformin among established glucose-lowering options for type 2 diabetes [2].
| Treatment approach | Main glucose-lowering action | Main limitation |
|---|---|---|
| Metformin | Reduces liver glucose production and improves insulin sensitivity | Gastrointestinal effects; unsuitable in severe renal impairment |
| Insulin therapy | Replaces or supplements insulin directly | Hypoglycaemia and weight gain can occur |
| Insulin-releasing medicines | Increase pancreatic insulin release | Hypoglycaemia and weight gain may occur |
Metformin is often selected early because it has extensive clinical experience, does not usually cause hypoglycaemia by itself, and is generally weight-neutral. Its limitations include gastrointestinal intolerance, the need for kidney-function assessment, and the small but serious risk of lactic acidosis in high-risk situations.
Insulin may be preferred when insulin deficiency is marked, glucose levels are very high, or pregnancy-specific treatment decisions require it. Insulin-releasing medicines may be considered in selected situations, though the risk of low blood glucose can be greater.
Treatment choices can change. A person whose glucose remains above target may need an additional medicine, a different class, or insulin. Cardiovascular disease, heart failure, chronic kidney disease, liver disease, and frailty can influence that decision.
The medicine should not be used in the following situations unless a qualified prescriber has specifically resolved the issue:
Specific issues include:
Kidney function is central to safe use. Reduced clearance can increase metformin exposure and raise the risk of lactic acidosis. The EMA product information also highlights renal impairment, hypoxic states, hepatic impairment, alcohol intake, and contrast procedures as situations requiring careful assessment [4].
Pregnancy and breastfeeding require an individual treatment decision.
Metformin is NOT for you if you have severe kidney impairment, metabolic acidosis, severe dehydration, or serious hypersensitivity to metformin. Talk to a qualified prescriber before using it if you have severe infection, shock, poor tissue oxygenation, severe liver problems, heavy acute alcohol exposure, or a procedure involving prolonged fasting.
Tell the prescriber about all medicines and supplements being used. Pregnancy and breastfeeding require an individual treatment decision. Diabetes itself can affect pregnancy outcomes, so treatment should not be stopped suddenly because pregnancy is suspected.
Digestive symptoms are the most familiar adverse effects of metformin. In clinical trials of immediate-release metformin, diarrhoea occurred in about 53% of participants and nausea or vomiting in about 26%; rates vary between studies and formulations .
Common effects include:
These effects often appear after starting treatment or increasing the dose. They may improve when the tablet is taken with food and the dose is increased gradually.
Do not ignore severe or persistent symptoms. Repeated vomiting, marked weakness, rapid breathing, severe abdominal pain, unusual sleepiness, or feeling cold can require urgent assessment because they may signal lactic acidosis, a rare but serious complication.
Long-term treatment can reduce vitamin B12 absorption in some patients. Symptoms of deficiency may include persistent tiredness, a sore or inflamed tongue, numbness, pins and needles, balance problems, or pallor. The risk is more relevant with prolonged treatment, higher doses, anaemia, or other factors that reduce B12 levels.
Metformin alone rarely causes low blood glucose because it does not directly increase insulin release. Hypoglycaemia becomes more likely when it is combined with insulin or an insulin-releasing medicine, when meals are missed, or during heavy alcohol intake.
A practical detail is easy to overlook: a temporary stomach illness can change the safety profile of metformin. Dehydration reduces kidney perfusion and can increase medicine accumulation, especially in people with pre-existing kidney impairment.
Several everyday mistakes can reduce tolerability or create avoidable risk:
One practical pattern appears repeatedly: people often blame every stomach symptom on food and continue taking metformin during several days of vomiting. Dehydration changes the risk, so sick-day instructions matter.
Another mistake is expecting an immediate feeling of improvement. Metformin changes glucose handling; it does not usually produce a noticeable sensation after each tablet.
In clinical practice, doctors usually judge metformin by the glucose response, glycated haemoglobin, kidney function, and the person's ability to tolerate treatment. A lower dose that is taken consistently may be more useful than a higher dose that causes daily diarrhoea.
Doctors also assess the reason for poor control before simply increasing the dose. Missed tablets, illness, steroid treatment, reduced activity, changed meals, and incorrect timing can all raise glucose levels.
A clinician will normally review kidney function at baseline and at intervals during therapy. Longer treatment may also prompt attention to vitamin B12, especially when anaemia or nerve symptoms appear.
The main advantages are its established role in type 2 diabetes, low hypoglycaemia risk when used alone, and lack of usual weight gain. The trade-offs are gastrointestinal intolerance, kidney-related restrictions, contrast-procedure interruptions, and the need to monitor for B12 deficiency during prolonged use.
WHO diabetes guidance supports combining glucose-lowering treatment with lifestyle measures, education, and regular monitoring rather than relying on tablets alone [5]. That does not mean metformin is ineffective; it reflects the way type 2 diabetes changes over time.
Yes. Metformin hydrochloride is used to improve blood-glucose control in adults with type 2 diabetes. The European Medicines Agency describes metformin as an option when diet and physical activity do not provide adequate control, with kidney function guiding safe use. The EMA product information available in 2023 also describes its use in adults and selected paediatric patients with type 2 diabetes.
Glucose readings may begin to change after treatment starts, while glycated haemoglobin reflects the average response over several weeks. The American Diabetes Association treatment standards published in 2025 assess diabetes control through ongoing glucose monitoring and periodic glycated haemoglobin testing. The response depends on dose, adherence, meals, physical activity, kidney function, and other treatments.
Metformin used alone has a low risk of hypoglycaemia because it does not directly stimulate insulin release. The risk increases when it is combined with insulin or medicines that increase pancreatic insulin secretion. WHO diabetes guidance from 2023 supports reviewing the complete treatment regimen when low-glucose episodes occur rather than blaming metformin automatically.
Severe vomiting or diarrhoea can cause dehydration and reduce kidney function, making continued metformin less suitable temporarily. NHS sick-day guidance published in 2024 advises specific temporary medication changes during significant dehydration, with treatment restarted after normal eating and drinking return according to the care plan. Persistent vomiting, rapid breathing, severe weakness, or confusion requires urgent medical assessment.
Long-term metformin use can reduce vitamin B12 absorption in some people. NICE guidance updated in 2024 recommends considering B12 testing when symptoms or risk factors suggest deficiency, including anaemia, nerve symptoms, or prolonged treatment. Testing and replacement can often address the problem while the diabetes regimen is reviewed.
Some CT scans use iodinated contrast, which can affect kidney function in susceptible patients. The FDA metformin prescribing information revised in 2024 requires a specific assessment around certain contrast procedures, based on kidney function and the type of imaging. Tell the imaging team about metformin before the scan so the correct temporary-interruption plan can be applied.
Metformin is prescribed to improve glucose control in type 2 diabetes, not as a dedicated weight-loss treatment. Some people lose a small amount of weight or avoid weight gain, while others notice little change. The American Diabetes Association standards from 2025 place weight management within a broader diabetes plan that includes food choices, activity, sleep, and other treatment factors.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first week brought loose stools after breakfast. Taking the tablet halfway through the meal helped, and the symptoms became less noticeable by the third week. I did not feel a sudden change, but my readings became more consistent.
The medicine itself was manageable when taken with dinner. My main difficulty was remembering the morning dose on workdays, so I linked it to breakfast rather than taking it whenever I remembered.
I stopped after several days of nausea because I expected the side effects to disappear immediately. Restarting at the prescribed pace was easier than the first attempt, but the experience showed me that dose increases should not be rushed.
My glucose readings improved gradually. A later blood test showed low B12, so the treatment plan included monitoring and replacement rather than simply abandoning metformin.
